Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of PF-06648671 in Healthy Subjects
NCT02316756Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06648671 in Alzheimer's disease (AD) (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of participants with AEs and SAEs, Supine vital sign measurement and 2 more. Started Dec 2014; status: completed.
02
Drugs
PF-06648671
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02316756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316756.